The latest biotech news

News and Trends 19 Dec 2017

Giving Molecular Combing the Golden Coat It Deserves

The novel spin given to some traditional and established technologies can be astounding. They might have been around for decades, applied in the same way over and over again, and yet, at some point, somebody comes along, observes it in a new light and gives it a brand new polish. One such technology is called […]

December 19, 2017 - 5 minutesmins - By External Contributor

granulomatous disease orchard therapeutics

News and Trends 18 Dec 2017

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Dec 2017

Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval

An EMA committee has supported an allogeneic stem cell therapy for the first time, as TiGenix’s Crohn’s disease candidate is backed for approval. TiGenix and its Japanese partner, Takeda, are developing a stem cell therapy for Crohn’s disease – an autoimmune disease affecting the gastrointestinal tract. This morning, the companies have revealed that their candidate, Cx601, has received the backing […]

December 18, 2017 - 3 minutesmins - By Alex Dale

hpv cancer isa pharmaceuticals regeneron

News and Trends 18 Dec 2017

Dutch and US Biotechs Team Up Against HPV-related Cancer

ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Dec 2017

Science and Art Join Forces to Challenge our Anthropocentric Worldviews

Western culture seems to revolve exclusively around humans. It seems that we have forgotten the existence and the needs of all other organisms, from microscopic bacteria and fungi that make our food and medicines to the chickens and cows that feed us. But is this anthropocentric behavior justified? What are the consequences of our destructive attitude […]

December 16, 2017 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Dec 2017

Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster?

GW Pharma might be about to join the likes of Genmab in the biotech blockbuster club, with its epilepsy drug predicted to achieve sales of close to $1B in 2018. GW Pharma develops therapies for a range of diseases, including autism, epilepsy and brain cancer using its cannabinoid product platform. In a rundown of the top 10 […]

December 15, 2017 - 2 minutesmins - By Alex Dale

News and Trends 15 Dec 2017

Abivax Spots an Extra Benefit of its Potential HIV Cure

Phase IIa data confirms that Abivax’s potential HIV cure not only reduces viral reservoir but it also has anti-inflammatory effects. Abivax targets the immune system to fight viral infections, including human immunodeficiency virus (HIV), as well as autoimmune diseases. The company has now confirmed the preliminary results from its first cohort of patients in a […]

December 15, 2017 - 2 minutesmins - By Alex Dale

News and Trends 14 Dec 2017

The FDA Fast Tracks Therapy for Rare Disease Causing Copper Accumulation

The FDA is speeding up the process for regulatory approval of WTX101, a therapy for Wilson’s disease that could significantly improve the standard of care. Wilson Therapeutics, in Stockholm, has convinced the FDA to include its drug WTX101 (bis-choline tetrathiomolybdate) in its Fast Track program. This move will speed up the approval of the drug, […]

December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Dec 2017

Someone’s Popular! Gilead is Just One Big Name Investing in this Vaccine Biotech

Gilead has joined a growing list of powerful investors that want to help Hookipa Biotech develop its vaccine technology by participating in its Series C fundraising. Hookipa Biotech, one of October’s biotechs of the week, develops vaccines for cancer and infectious diseases. Its pipeline includes two platforms: Vaxwave and TheraT, which are targeted at cytomegalovirus infections and […]

December 14, 2017 - 2 minutesmins - By Alex Dale

News and Trends 14 Dec 2017

A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies?

Researchers from the University of Zurich have determined the structure of a chloride channel, which could be a target for new drugs to treat cystic fibrosis. Researchers at the University of Zurich have found a new target for future cystic fibrosis treatments. The study, published in Nature, has uncovered the structure of a protein that could help to […]

December 14, 2017 - 3 minutesmins - By Alex Dale

gene therapy osteoarthritis genequine2 1

News and Trends 14 Dec 2017

German Biotech’s Gene Therapy for Osteoarthritis Plucked by US Pharma

GeneQuine’s gene therapy for osteoarthritis in the knee has been acquired by US pharma company Flexion Therapeutics for up to $64M. GeneQuine is developing a gene therapy for the treatment of osteoarthritis. It uses helper-dependent adenoviruses, which provide long-term expression, a higher packaging capacity, reduced immunogenicity and they do not integrate into the host genome. It seems like yesterday […]

December 14, 2017 - 3 minutesmins - By Alex Dale

News and Trends 14 Dec 2017

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Today, the Belgian biotech has announced that it has raised a very impressive $231M (€195M) following positive results at ASH. The company […]

December 14, 2017 - 1 minutemin - By Alex Dale

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Giving Molecular Combing the Golden Coat It Deserves

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval

Dutch and US Biotechs Team Up Against HPV-related Cancer

Science and Art Join Forces to Challenge our Anthropocentric Worldviews

Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster?

Abivax Spots an Extra Benefit of its Potential HIV Cure

The FDA Fast Tracks Therapy for Rare Disease Causing Copper Accumulation

Someone’s Popular! Gilead is Just One Big Name Investing in this Vaccine Biotech

A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies?

German Biotech’s Gene Therapy for Osteoarthritis Plucked by US Pharma

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!